US-based pharmaceutical firm NanOlogy has started patient enrolment in a Phase II clinical trial of intraperitoneal (IP) NanoPac (nanoparticle paclitaxel) sterile suspension to treat ovarian cancer.

Part of the firm’s nanoparticle technology platform, NanoPac is stable without coating agents and can be suspended in simple vehicles before use.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The randomised, open-label, parallel Phase II trial is designed to assess the safety and efficacy of IP instillation of 100mg/m², 200mg/m², 300mg/m² and 400mg/m² NanoPac given immediately after cytoreductive (debulking) surgery.

NanoPac administered in combination with standard-of-care (SOC) intravenous (IV) chemotherapy of carboplatin and paclitaxel will be compared to SOC IV chemotherapy alone.

NanOlogy Medical Affairs vice-president Gere diZerega said: “Systemically administered paclitaxel has been shown to be effective in ovarian cancer but is limited by its adverse effects.

“Systemically administered paclitaxel has been shown to be effective in ovarian cancer but is limited by its adverse effects.”

“We are attempting to show that a single, IP-instilled dose of NanoPac will effectively treat the cancer with high locally sustained concentrations of the drug and no contribution to systemic adverse effects.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary outcome measures of the trial are treatment-emergent adverse events and progression-free survival at 12 months, while the secondary outcomes include maximum plasma concentration of paclitaxel.

Expected to be complete by September 2019, the trial will include approximately 61 subjects.

In addition to ovarian cancer, NanoPac sterile suspension is being studied for the treatment of prostate cancer and pancreatic cancer through an intratumoral route, and for treating pancreatic mucinous cyst by intracystic administration.